Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2015-06-01 Legal Proceedings Report
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
NeuroVive reports topline results of phase III CIRCUS study in acute myocardial infarction
Legal Proceedings Report Classification · 1% confidence The document is explicitly titled "NEWS RELEASE" and announces "topline results of phase III CIRCUS study in acute myocardial infarction." It details the outcome (did not meet primary clinical endpoint) and discusses future plans for data analysis and commercialization. This format—a press release announcing key financial or operational results (in this case, clinical trial results which heavily impact future earnings/operations)—is characteristic of an Earnings Release (ER). It is not a full Annual Report (10-K), an Interim Report (IR), or a detailed Management Discussion & Analysis (MDA). It is the initial announcement of period-specific performance outcomes.
2015-06-01 English
NeuroVive meddelar topline-resultat från fas III-studien (CIRCUS) med CicloMulsion® för behandling av akut hjärtinfarkt
Earnings Release Classification · 1% confidence The document is explicitly titled and formatted as a "PRESSMEDDELANDE" (Press Release) dated 2015-06-01. It announces the topline results of a Phase III clinical study (CIRCUS) for a drug candidate (CicloMulsion®). This type of announcement, which provides key initial results and commentary from management regarding clinical trial outcomes, fits best under the category of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific announcement of financial/operational results (even if clinical trial results), and not a full quarterly/annual report (10-K or IR), 'ER' is the most appropriate fit for a significant operational update that impacts future earnings potential. It is not a transcript (CT), a formal annual report (10-K), or a dividend notice (DIV). Given the nature of the announcement—a major clinical trial result update—it functions similarly to an earnings highlight release. Q2 2015
2015-06-01 Swedish
Ändring av antal aktier och röster i NeuroVive Pharmaceutical AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a 'PRESSMEDDELANDE' (Press Release) dated 2015-05-29. The core content announces a change in the total number of shares and votes following a new share issue ('nyemission') approved by the AGM and the board. This directly relates to a change in the company's capital structure (share count). This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital changes. It is not a general earnings release (ER), a full annual report (10-K), or a dividend notice (DIV).
2015-05-29 Swedish
NeuroVive Pharmaceutical AB (publ) - amendment number of shares and votes
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a 'NEWS RELEASE' dated May 29, 2015, titled 'NeuroVive Pharmaceutical AB (publ) - amendment number of shares and votes'. The text explicitly states that due to a new share issue resolved by the AGM and decided by the Board, the total number of shares and votes has increased. This directly relates to a change in the company's capital structure via share issuance. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). Although it mentions the AGM resolution, the core subject is the resulting share count change, not the AGM materials themselves (AGM-R) or the voting results (DVA). It is not a general regulatory filing (RNS) because a more specific category exists.
2015-05-29 English
Aktieförsäljning utanför marknaden efter genomförda aktieinbyten
Director's Dealing Classification · 1% confidence The document is a press release dated May 26, 2015, announcing that an insider (the Head of Research, Eskil Elmér) sold 85,000 shares outside the market to cover taxes resulting from prior share swaps. This transaction involves a director/executive dealing in the company's shares. This directly corresponds to the definition of 'Director's Dealing' (Code: DIRS). Although it is a press release, the core subject matter is the insider transaction, making DIRS more specific than a general Regulatory Filing (RNS) or Report Publication Announcement (RPA). The document length (3396 chars) is short, but the content is a specific disclosure, not just an announcement that a report is available.
2015-05-26 Swedish
Sale of shares off the market following share exchange program
Share Issue/Capital Change Classification · 1% confidence The document is a 'NEWS RELEASE' announcing that an 'insider registered person' (the chief scientific officer) has 'sold 85.000 shares in NeuroVive off the market' following a share exchange program. This directly relates to personal share transactions by company directors and executives (insider trades). This aligns perfectly with the definition for Director's Dealing (DIRS). Although it is a news release, the core content is the insider transaction disclosure, making DIRS more specific than a general Regulatory Filing (RNS) or Report Publication Announcement (RPA). The document length is moderate, but the subject matter is highly specific to insider trading disclosure.
2015-05-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.